

NEUROLOGIX INC/DE  
Form 8-K  
October 17, 2006

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

---

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported) October 17, 2006

Neurologix, Inc.

(Exact Name of Registrant as Specified in Charter)

Commission File Number: 000-13347

Delaware

(State or other Jurisdiction of

Incorporation)

06-1582875

(I.R.S. Employer Identification No.)

One Bridge Plaza, Fort Lee, New Jersey 07024

(Address of Principal Executive Offices)

(Zip Code)

(201) 592-6451

(Registrant's telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

## Edgar Filing: NEUROLOGIX INC/DE - Form 8-K

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
- 

### **Item 7.01. Regulation F-D Disclosure**

On October 17, 2006, the Company issued a press release regarding the completion of the Phase I study for its Parkinson's product. On the same date, Dr. Matthew J. During, a consultant to the Company and a member of its scientific advisory board, presented updated clinical data from such study at the Annual Meeting of The Society for Neuroscience in Atlanta, Georgia. Copies of the press release and Dr. During's slide presentation are filed herewith as Exhibits 99.1 and 99.2, respectively.

The information, including the exhibits attached hereto, in this Current Report is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Current Report shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, except as otherwise expressly stated in such filing.

### **Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits

- 99.1 Press release issued on October 17, 2006
  - 99.2 Slide presentation made on October 17, 2006
-

Edgar Filing: NEUROLOGIX INC/DE - Form 8-K

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: October 17, 2006

NEUROLOGIX, INC.

By: /s/ Marc L. Panoff  
Marc L. Panoff  
Chief Financial Officer, Secretary and Treasurer